MENU
FEB 26, 2020 6:00 AM PST

Keynote Presentation: Discovery and Development of a Novel First-in-Class Resuscitative Agent

C.E. Credits: Florida CE P.A.C.E. CE
Speaker
  • Chairman & Chief Executive Officer of Pharmazz, Inc.; Adjunct Professor, Colleges of Pharmacy and Graduate Studies, Midwestern University; Department of Bioengineering, University of Illinois
    BIOGRAPHY

Abstract

Centhaquine (previously used names, centhaquin and PMZ-2010; International Non-proprietary Name (INN) recently approved by WHO is centhaquine) is being developed by us as a first-in-class resuscitative agent for treating hypovolemic shock. It acts on the venous α2B-adrenergic receptors and enhances venous return to the heart, in addition, it produces arterial dilatation by acting on central α2A-adrenergic receptors to reduce sympathetic activity and systemic vascular resistance. Enhanced cardiac output and blood flow to the vital organs, prevents organ failure and improves survival and recovery of hypovolemic shock patients. Toxicological studies showed high safety margin in preclinical studies. Its safety and tolerability have been demonstrated in a human phase I study in 25 subjects (NCT02408731). Phase II human studies showed extraordinary efficacy in patients with hypovolemic shock. A prospective, multi-centric, randomized, double-blind, parallel, saline controlled phase II study was carried out with centhaquine as a resuscitative agent for hypovolemic shock (NCT04056065). A total of 50 subjects met inclusion and exclusion criteria and were included in the study. Systolic and diastolic blood pressure in control group improved but in centhaquine group a much more significant increase in systolic and diastolic blood pressure was observed 48 hours after resuscitation. Blood lactate levels decreased from 4.30 ± 0.96 at baseline to 3.19 ± 1.07 (p=0.7729) at day 3 in control and from 4.34 ± 0.78 at baseline to 1.44 ± 0.13 (p=0.0012) at day 3 in centhaquine cohort. Two patients died in control and none in centhaquine cohort. No incidence of drug related adverse event occurred. A phase III multi-centric, randomized, double-blind, parallel, controlled phase-III efficacy clinical study of centhaquine therapy in patients with hypovolemic shock (NCT04045327) has been completed in 105 patients with positive results. Centhaquine is an innovative drug product that is likely to provide significant benefit to an unmet life-threatening medical condition of hypovolemic shock.


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
OCT 12, 2021 9:00 AM PDT
C.E. CREDITS
OCT 12, 2021 9:00 AM PDT
Date: October 12, 2021 Time: 9:00am (PDT), 12:00pm (EDT) SCIEX’s next-generation Biologics Explorer software is an innovative platform for the comprehensive and deep characterization o...
JUL 15, 2021 8:00 AM PDT
C.E. CREDITS
JUL 15, 2021 8:00 AM PDT
Date: July 15, 2021 Time: 8:00am (PDT), 11:00am (EDT) High dimensional full spectrum flow cytometry grants unprecedented access to previously unattainable parameters in cellular biology. Flu...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
Loading Comments...
Show Resources